ReviewFrontiers in oncology2025
Prokaryotic organelle mitochondria drive tumorigenesis: "the original sin".
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- DARS2 serves as an independent prognostic factor and participates in multiple biological processes in bladder urothelial carcinoma.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondria preserve bacterial traits because of their endosymbiotic origin, and their alterations in cancer cells reflect these prokaryotic-like traits. One such trait is the Warburg effect, wherein tumor cells rely primarily on aerobic glycolysis instead of oxidative phosphorylation. Cancer cells also exhibit metabolic abnormalities, such as an uncoupled electron transport chain and a truncated tricarboxylic acid (TCA) cycle, potentially generating additional energy. Intermediates from the disrupted TCA cycle can regulate key genes involved in cell differentiation, apoptosis, and tumor suppression while promoting aerobic glycolysis, angiogenesis, and resistance to cell death. Mitochondria-related gene mutations, particularly in D-loop and TCA-related enzymes, have been identified as key drivers of prokaryotic transformation in diverse cancers. Furthermore, the metabolic activity of cancer mitochondria results in the production of essential biosynthetic precursors for nucleotide synthesis and lipid synthesis, supporting tumor growth. Mitochondria also contribute to tumorigenesis by promoting inflammation and iron metabolism disorders. Mitochondrial dysfunctions have raised interest in the use of mitochondria-targeted anticancer strategies as possible cancer treatments, although their clinical application requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.